Some of these drugs have been already available in trials for NSCLC patients and specifically target MET (telisotuzumab vedotin), HER2 (trastuzumab deruxtecan), HER3 (patritumab deruxtecan), TROP2 (datopotamab deruxtecan and SKB264). The gene discussed is ERBB3; the disease is non-small cell lung carcinoma.